statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will...

Alltrna Announces Updates to Its Board of Directors

Alltrna Announces Updates to Its Board of Directors Alltrna Announces Updates to Its Board of Directors PR Newswire CAMBRIDGE, Mass., July 17, 2024 Chris Schade appointed as Board ChairpersonLynne...

Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression

Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial...

Syros to Participate in Upcoming Investor Conferences

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company...

Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United...

Syros Pharmaceuticals (NASDAQ:SYRS) Rating Reiterated by HC Wainwright

Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report)s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a report released on Monday, Benzinga reports. They...

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of a...

Syros Pharmaceuticals (SYRS, $5.04) Aroon Indicator entered a Downtrend on April 01, 2024.

For the last three days, A.I.dvisor has detected that SYRS's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Volume	86,652.00
52-Wk High	$8.17
52-Wk Low	$2.09

SYRS Syros Pharmaceuticals Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals